Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/25748
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCosters, Lars-
dc.contributor.authorGielen, Jeroen-
dc.contributor.authorEelen, Piet L.-
dc.contributor.authorvan Schependom, Jeroen-
dc.contributor.authorLaton, Jorne-
dc.contributor.authorVan Remoortel, Ann-
dc.contributor.authorVANZEIR, Ellen-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorSeeldrayers, Pierrette-
dc.contributor.authorHaelewyck, Marie-Claire-
dc.contributor.authorD'Haeseleer, Miguel-
dc.contributor.authorD'hooghe, Marie-Beatrice-
dc.contributor.authorLangdon, Dawn-
dc.contributor.authorNagels, Guy-
dc.date.accessioned2018-03-09T14:12:39Z-
dc.date.available2018-03-09T14:12:39Z-
dc.date.issued2017-
dc.identifier.citationMULTIPLE SCLEROSIS AND RELATED DISORDERS, 18, p. 33-40-
dc.identifier.issn2211-0348-
dc.identifier.urihttp://hdl.handle.net/1942/25748-
dc.description.abstractBackground: The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is a fast, easy-to-administer and already widely validated neuropsychological battery for cognition in multiple sclerosis. Objective: The goals of our study were to validate the BICAMS in a Belgian Dutch-speaking population and to investigate to what extent including extensive versions of two of the three BICAMS subtests improved its psychometric qualities. Methods: Ninety-seven persons with MS and ninety-seven healthy controls were included and group-matched on age, education level and gender. All participants performed the BICAMS with an extensive version of the CVLT-II and BVMT-R. Results: The SDMT and BVMT-R were able to dissociate between the MS and healthy control group, while the CVLT-II was not. Distributions of CVLT-II scores suggest learning effects in the MS group, indicating the need for alternative word lists or the construction of an adapted version fitted for repeated administration. Including the full CVLT-II and BVMT-R did not markedly improve the psychometric qualities of the BICAMS. Conclusion: This study validates the BICAMS in a Belgian Dutch-speaking population and facilitates the use of it in clinical practice, while providing evidence that including full versions of the CVLT-II and BVMT-R does not increase its psychometric qualities markedly.-
dc.description.sponsorshipMD has received travel grants, consultancy and speaker fees from Biogen, Teva, Novartis and Genzyme Sanofi. DL is a consultant for Novartis, Bayer, TEVA, Biogen and Merck, part of a speaker bureau for Almirall, TEVA, Biogen, Novartis, Bayer and Excemed and holds research grants from Novartis, Biogen and Bayer. All are paid into DL's university. GN holds a research chair by Merck and Novartis. None of these are likely to be relevant in the context of this manuscript.-
dc.language.isoen-
dc.publisherELSEVIER SCI LTD-
dc.subject.otherMultiple sclerosis; Cognition; BICAMS-
dc.subject.otherMultiple sclerosis; Cognition; BICAMS-
dc.titleDoes including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study-
dc.typeJournal Contribution-
dc.identifier.epage40-
dc.identifier.spage33-
dc.identifier.volume18-
local.format.pages8-
local.bibliographicCitation.jcatA1-
dc.description.notes[Costers, Lars; Gielen, Jeroen; van Schependom, Jeroen; Laton, Jorne; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Nagels, Guy] Vrije Univ Brussel, Ctr Neurosci, Pleinlaan 2, B-1050 Brussels, Belgium. [Haelewyck, Marie-Claire; Nagels, Guy] Univ Mons, Fac Psychol & Sci Educ, Mons, Belgium. [Eelen, Piet L.; Van Remoortel, Ann; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Nagels, Guy] Natl MS Ctr Melsbroek, Steenokkerzeel, Belgium. [van Schependom, Jeroen] Vrije Univ Brussel, UZ Brussel, Radiol, Brussels, Belgium. [Vanzeir, Ellen; Van Wijmeersch, Bart] Revalidatie & MS Centrum Overpelt, Overpelt, Belgium. [Van Wijmeersch, Bart] Univ Hasselt, Biomed Onderzoeksinst, Hasselt, Belgium. [Seeldrayers, Pierrette] Ctr Hosp Univ Charleroi, Charleroi, Belgium. [Langdon, Dawn] Royal Holloway Univ London, London, England.-
local.publisher.placeOXFORD-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.msard.2017.08.018-
dc.identifier.isi000415341300008-
item.contributorCosters, Lars-
item.contributorGielen, Jeroen-
item.contributorEelen, Piet L.-
item.contributorvan Schependom, Jeroen-
item.contributorLaton, Jorne-
item.contributorVan Remoortel, Ann-
item.contributorVANZEIR, Ellen-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorSeeldrayers, Pierrette-
item.contributorHaelewyck, Marie-Claire-
item.contributorD'Haeseleer, Miguel-
item.contributorD'hooghe, Marie-Beatrice-
item.contributorLangdon, Dawn-
item.contributorNagels, Guy-
item.fullcitationCosters, Lars; Gielen, Jeroen; Eelen, Piet L.; van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn & Nagels, Guy (2017) Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study. In: MULTIPLE SCLEROSIS AND RELATED DISORDERS, 18, p. 33-40.-
item.validationecoom 2018-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
crisitem.journal.issn2211-0348-
crisitem.journal.eissn2211-0356-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1-s2.0-S221103481730202X-main.pdf
  Restricted Access
Published version710.04 kBAdobe PDFView/Open    Request a copy
accepted_manuscript_BICAMS.pdfPeer-reviewed author version1.07 MBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

37
checked on Sep 30, 2025

WEB OF SCIENCETM
Citations

37
checked on Oct 4, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.